Who makes Biphemanil?

Biphemanil is developed by Merck & Co..

What development phase is Biphemanil in?

Biphemanil is FDA-approved (marketed).

What is the generic name of Biphemanil?

DIPHEMANIL is the generic (nonproprietary) name of Biphemanil.

Last reviewed 2026-04-20 · How we verify

Biphemanil (DIPHEMANIL)

Merck & Co. · FDA-approved approved Small molecule Quality 15/100

At a glance

Generic name	DIPHEMANIL
Sponsor	Merck & Co.
Drug class	diphemanil
Target	Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M3
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved
First approval	1976

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Biphemanil CI brief — competitive landscape report
Biphemanil updates RSS · CI watch RSS
Merck & Co. portfolio CI